![]()
|
|
||||||||
J. Biol. Chem., Vol. 277, Issue 32, 28512-28520, August 9, 2002
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
-Synuclein, a Molecular
Chaperone*
,
,
,
¶
From the
Department of Microbiology and Brain Korea
21 Project of Medical Sciences, Yonsei University College of
Medicine, Seoul 120-752, Korea and the § School of
Chemistry, College of Natural Sciences, Seoul National University,
Seoul 151-747, Korea
Received for publication, December 15, 2001, and in revised form, April 29, 2002
| |
ABSTRACT |
|---|
|
|
|---|
The mechanism of the chaperone action of sHSPs, on the other hand, is
comparatively well understood. sHSPs protect substrate proteins from
stress (e.g. heat, chemicals, etc.) by forming high molecular weight (HMW) complexes with partially unfolded substrate proteins (27, 32-40). However, alone sHSPs do not have the ability to
protect enzymes from thermal inactivation or to promote their functional refolding after denaturation (31, 39, 41, 42), although a
few exceptional cases with marginal effects have been reported (30, 33,
43-46). sHSPs have, therefore, been classified as "junior
chaperones" (47). sHSPs share many properties, for example, they have
extensive amino acid sequence similarity, and are found as large,
aggregated complexes of average mass 200-800 kDa (reviewed in Refs. 48
and 49). The charged C-terminal domain (also called the In this study, we investigated the molecular mechanism of the chaperone
action of Materials--
GSH, dithiothreitol (DTT),
1-chloro-2,4-dinitrobenzene, and
isopropyl- Purification of Construction of DHFR-Syn-(96-140) Expression Vector--
The
protein coding region of dihydrofolate reductase (DHFR) was subcloned
into an E. coli expression vector, pRSETA, using BamHI and HindIII restriction sites (pDHFR). The
protein coding region of the C-terminal acidic tail of Bacterial Expression and Purification of
DHFR-Syn-(96-140)--
The DHFR-Syn-(96-140) fusion construct was
transformed into the E. coli strain BL21(DE3) for protein
expression. The transformed bacteria were grown in a LB medium with 0.1 mg/ml ampicillin at 37 °C to an A600 of 0.8, then cultured for a further 4 h after being induced with 0.5 mM isopropyl- Chaperone-like Activity Assay--
The ability of chaperone
proteins to prevent heat-induced aggregation of substrate proteins (GST
and aldolase) was monitored as described previously (25). Briefly,
substrate proteins (0.2 mg/ml as a final concentration) in PBS (pH 7.4)
were incubated with each chaperone protein at 65 °C for specified
times (see figure legends) in a cuvette. Light scattering was then
monitored at 360 nm as a function of time, using a spectrophotometer
(Beckman DU-650). The ability of the chaperone proteins to prevent
chemically induced substrate protein (insulin and lysozyme) aggregation
was monitored as described previously (24, 25). Substrate proteins (0.5 mg/ml as a final concentration) in 10 mM phosphate buffer (pH 7.4) were incubated with the indicated amounts of each chaperone protein at room temperature (see figure legends). DTT was added, to a
final concentration of 20 mM, to commence the denaturation and precipitation of substrate proteins. Light scattering was then
monitored at 360 nm using a spectrophotometer (Beckman DU-650). In
addition, luciferase (0.1 mg/ml in PBS as a final concentration) was
incubated with each chaperone protein for 10 min at 65 °C in a
cuvette, and light scattering was monitored at 360 nm (Fig. 6B). For the insulin aggregation assay in Fig.
6A, insulin alone (0.5 mg/ml as a final concentration in 10 mM phosphate buffer, pH 7.4) or a mixture of insulin and
GST-Syn-(96-140) (0.5 mg/ml each as a final concentration) was
preincubated for 5 min at 59 °C in a thermostatic cell holder, and
this temperature was maintained during the chaperone assay. After
adding 2 mM DTT as a final concentration, the absorbance
was measured at 360 nm as a function of time.
Gel-filtration Chromatographic Analysis of the High Molecular
Weight Complexes--
Individual solutions of each chaperone protein
and substrate protein (GST or aldolase, final concentration of 0.1-0.2
mg/ml in PBS), or mixtures of chaperone and substrate proteins (final concentration of 0.2-0.5 mg/ml chaperone protein with 0.1-0.2 mg/ml
substrate protein in PBS) were either heat treated (65 °C for 10 min) or not heat-treated, and then centrifuged for 10 min at 13,000 rpm
to remove precipitated proteins. 500 µl of each supernatant was
loaded onto the Superdex 75 HR 10/30 column (Amersham Biosciences) equilibrated in PBS (pH 7.4), and the proteins were eluted at a flow rate of 1 ml/min at room temperature. Fractions corresponding to each protein peak were collected and analyzed in 12%
SDS-polyacrylamide gels. To detect GST Activity Assay--
The enzymatic activity of GST was
assayed using a chromogenic substrate, 1-chloro-2,4-dinitrobenzene, as
described previously (60). The GST enzyme was added to the substrate
solution (1 mM GSH and 2 mM
1-chloro-2,4-dinitrobenzene in 0.1 M phosphate buffer, pH
7.4) to a final concentration of 20 µg/ml and incubated at 37 °C
for 10 min. Enzyme activity was measured as an increased absorbance at
350 nm, corresponding to the maximum absorbance of
1-S-glutathionyl-2,4-dinitrobenzene, using the Spectramax
250 microplate reader (Molecular Devices, Menlo Park, CA).
Phosphatase Activity Assay--
The catalytic activity of
protein-tyrosine phosphatase-1B was assayed at 37 °C for 60 min in a
reaction mixture (0.2 ml) containing 10 mM
p-nitrophenyl phosphate as substrate. The buffer used
was 20 mM Tris-HCl buffer (pH 7.4) containing 0.15 M NaCl, 1 mM EDTA, and 2 mM DTT.
The reaction was initiated by adding enzyme and quenched after 60 min
by the addition of 1 ml of 1 N NaOH. The amount of
p-nitrophenol released was determined by measuring the absorbance at 405 nm.
The C-terminal Acidic Tail Is Necessary, but Insufficient for the
Chaperone Activity of
We next compared the chaperone activity of the The N-terminal Region Mediates Substrate Protein
Binding--
Small molecular chaperones, such as small heat shock
proteins, The Binding Domain Can Be Substituted by Other Proteins--
This
study shows that the binding domain and solubilizing domain were
structurally distinct in
Like other small molecular chaperone proteins, GST-Syn-(96-140) formed
a HMW complex when incubated with aldolase, a substrate protein, for 10 min at 65 °C (Fig. 4).
GST-Syn-(96-140) also formed a HMW complex with GST when the proteins
were co-incubated at 65 °C (data not shown). Unlike DHFR-Syn-(96-140) Also Has Chaperone Activity--
To address
whether any proteins containing the acidic tail of The Binding Domain Determines the Efficiency and Specificity of
Chaperone Function--
Our data show that engineered chaperone
proteins (Syn-(61-140), GST-Syn-(96-140), and DHFR-Syn-(96-140))
containing the acidic tail of GST-Syn-(96-140) Does Not Protect Enzymes from Heat-induced
Inactivation--
Small molecular chaperone proteins are generally
known to be inefficient at preventing the thermal inactivation of
enzymes (31, 39-42, 65), although some small molecular chaperone
proteins are reported to have a marginal potential to protect certain
enzymes from thermal inactivation (30, 33, 43-47). Previously, we
showed that
-Synuclein, an acidic neuronal protein of 140 amino acids, is extremely heat-resistant and is natively unfolded.
Recent studies have demonstrated that
-synuclein has chaperone
activity both in vitro and in vivo, and that
this activity is lost upon removing its C-terminal acidic tail.
However, the detailed mechanism of the chaperone action of
-synuclein remains unknown. In this study, we investigated the
molecular mechanism of the chaperone action of
-synuclein by
analyzing the roles of its N-terminal and C-terminal domains. The
N-terminal domain (residues 1-95) was found to bind to substrate
proteins to form high molecular weight complexes, whereas the
C-terminal acidic tail (residues 96-140) appears to be primarily
involved in solubilizing the high molecular weight complexes. Because
the substrate-binding domain and the solubilizing domain for chaperone
function are well separated in
-synuclein, the N-terminal-binding
domain can be substituted by other proteins or peptides. Interestingly,
the resultant engineered chaperone proteins appeared to display
differential efficiency and specificity in terms of the chaperone
function, which depended upon the nature of the binding domain. This
finding implies that the C-terminal acidic tail of
-synuclein can be
fused with other proteins or peptides to engineer synthetic chaperones
for specific purposes.
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
-Synuclein, a major constituent of Lewy bodies in Parkinson's
disease, is an acidic neuronal protein that is composed of 140 amino
acids (1-4).
-Synuclein is extremely heat-resistant and natively
unfolded with an extended structure primarily composed of random coils
(5-7).
-Synuclein consists of three distinct regions (reviewed in
Refs. 8-11). The N-terminal region of
-synuclein contains KTKEGV
repeats, which form amphipathic
-helixes that are reminiscent of the
lipid-binding domain of apolipoproteins (12). The central region of
-synuclein is composed of a very hydrophobic non-A
component of
Alzheimer's disease amyloid
(NAC)1 peptide, and the
acidic C-terminal region of
-synuclein is composed primarily of
acidic amino acids. Moreover, the amphipathic N-terminal and the
hydrophobic NAC regions are highly conserved between species, whereas
the C-terminal region is highly variable in size and in sequence
(reviewed in Refs. 8-11). In addition to
-synuclein, the
- and
-synucleins and synoretin, members of the synuclein family,
have been identified in humans (1, 2, 13, 14).
-Synuclein has been suggested to be implicated in the pathogenesis
of Parkinson's disease and related neurodegenerative disorders (reviewed in Refs. 8-11), and more recently, to be an important regulatory component of vesicular transport in neuronal cells (15).
Moreover,
-synuclein has been suggested to function as a chaperone
protein in vivo because it appears to bind many cellular proteins (16-22). In particular,
-synuclein shares regions of homology with 14-3-3 proteins (18), which are a family of ubiquitous cytoplasmic chaperones (23), and binds to 14-3-3 proteins as well as to
the ligands of 14-3-3 including PKC, BAD, and ERK (18). More
importantly,
-synuclein is overexpressed under stress conditions (18). Recently, the chaperone activity of
-synuclein in
vitro has been demonstrated by two research groups (24, 25). Like other small heat shock proteins (sHSPs), such as HSP25, HSP16, and
-crystallin (26-31),
-synuclein is able to prevent the thermally and chemically induced aggregation of substrate proteins. The other
synuclein family members, the
- and
-synucleins, also appear to
have this chaperone activity (24). However, the detailed mechanism of
the chaperone action of
-synuclein remains unknown. Interestingly,
the chaperone activity of
-synuclein is lost upon removing its
C-terminal acidic tail (24), suggesting that the acidic tail plays an
important role in the molecular chaperone function. Furthermore,
conformational changes induced in
-synuclein by environmental
factors and its consequent aggregation abolish the chaperone activity
of
-synuclein (25), which suggests that the natively unfolded
conformation might be essential for the substrate binding and
subsequent stabilization by
-synuclein.
-crystallin
domain) is well conserved in all members of the sHSP family, whereas
the hydrophobic N-terminal domain is variable in length and sequence
(49). The N-terminal domain is known to play a crucial role in
self-assembly and thus contributes to chaperone activity (38, 50),
whereas the C-terminal domain is known to be crucial for substrate
protein binding and stabilization (51). In particular, a 19-amino acid
peptide derived from the C-terminal domain has been shown to posses
substantial chaperone activity (52). The extended polar C-terminal tail (10-18 amino acid residues) is also important in the chaperone action
of sHSPs, and appears to fulfill many roles that are not completely
understood yet. First, the extended C-terminal tail of sHSPs is
believed to function as a solubilizer (26, 53-56). Moreover,
truncation of the C-terminal tail results in a significant decrease in
the chaperone function and stability of sHSPs (55, 57). In some sHSPs,
the flexible C-terminal tail also appears to interact directly with
substrate proteins (29, 54). Furthermore, the crystal structure of
HSP16 reveals that the C-terminal tail is also involved in the
organization of the HSP oligomer (27, 28).
-synuclein by analyzing the roles of the N-terminal and
C-terminal domains of
-synuclein in the molecular chaperone
function. Unlike the sHSPs, the substrate-binding domain and the
solubilizing domain for chaperone function appeared to be well
separated in
-synuclein.
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
-D-thiogalactopyranoside were purchased from
Sigma. Glutathione-Sepharose 4B was obtained from Peptron (Taejon,
Korea). Bovine plasma thrombin was supplied by Sigma. Leupeptin,
pepstatin, and phenylmethylsulfonyl fluoride were purchased from Roche
Molecular Biochemicals. Aldolase from rabbit muscle, insulin
from the bovine pancreas, lysozyme from chicken eggs, and luciferase
from the firefly (Photinus pyralis) were purchased from Sigma.
-Synuclein Deletion Mutants and GST-Synuclein
Fusion Proteins--
-Synuclein was overexpressed in
Escherchia coli and the recombinant protein was purified to
apparent homogeneity by taking advantage of the thermosolubility of the
protein and by using conventional column chromatography, as described
previously (6, 58). The GST protein encoded by the pGEX expression
vector was purified by affinity chromatography using
glutathione-Sepharose 4B beads, and further purified on an FPLC
gel-filtration column. The GST-
-synuclein fusion constructs,
pGST-Syn-(61-140) and pGST-Syn-(96-140), were generated by the
PCR amplification of the
-synuclein gene with specific primer sets
containing the BglII and SalI restriction sites
(59). The GST-synuclein fusion constructs were transformed into the
E. coli strain, BL21(DE3), and the recombinant GST-synuclein fusion proteins, GST-Syn-(61-140) and GST-Syn-(96-140), were purified by affinity chromatography using glutathione-Sepharose 4B beads. The
GST-synuclein fusion proteins were further purified on an FPLC
gel-filtration column. The
-synuclein deletion mutants, Syn-(61-140) and Syn-(96-140), were prepared from GST-Syn-(61-140) and GST-Syn-(96-140), respectively, by thrombin digestion of the fusion proteins.
-synuclein
(residues 96-140) was amplified by PCR with the 5'-oligonucleotide
primer GCGCGGTACCAAGGACCAGTTGGGCAAGAATG
containing the underlined KpnI restriction site and
3'-oligonucleotide primer
GCGCGTCGACTTAGGCTTCAGGTTCGTAGT containing the
underlined SalI restriction site. The amplified DNAs were
gel purified, digested with appropriate enzymes, then ligated into the
pDHFR vector that had been digested with the appropriate restriction
enzymes and gel purified. All constructs were verified by DNA sequencing.
-D-thiogalactopyranoside. The
cells were harvested by centrifugation at 10,000 rpm for 10 min,
resuspended in phosphate-buffered saline (PBS, pH 7.4), then disrupted
by ultrasonication. After removing the cell debris, the supernatants
were loaded onto a nickel-nitrilotriacetic acid column equilibrated
with a loading buffer (50 mM phosphate buffer (pH 8.0)
containing 0.3 M NaCl and 10 mM imidazole).
After washing with the loading buffer, the protein was eluted with 250 mM imidazole in the same buffer. The DHFR-Syn-(96-140)
fusion protein was further purified on an FPLC gel-filtration column.
The protein was concentrated and the buffer changed by Centricon
(Amicon, Beverly, MA).
-synuclein in the HMW complex, 25 µl of each fraction was loaded into a 12% SDS-polyacrylamide gel,
transferred onto a polyvinylidene difluoride membrane, and Western
blotted with rabbit polyclonal anti-
-synuclein antibodies.
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
-Synuclein--
Previous studies have shown
that
-synuclein has chaperone activity in vitro (24, 25).
Like other small molecular chaperone proteins,
-synuclein was able
to protect a variety of proteins from stress-induced aggregation.
Interestingly, the chaperone activity of
-synuclein was completely
lost upon removing its C-terminal acidic tail (24), which suggests that
the acidic tail was critical for its chaperone activity. We first asked
whether the acidic tail was sufficient to have the chaperone activity. To address this question, we constructed two deletion mutants encoding
either the acidic tail only (residues 96-140, Syn-(96-140)) or the
NAC region plus the acidic tail (residues 61-140, Syn-(61-140)), and
compared their chaperone activities with that of wild type
-synuclein. The effect of the deletion mutants on the heat-induced precipitation of substrate proteins was first investigated by using the
conventional chaperone activity assay. As shown in Fig. 1A, the C-terminal acidic tail
alone (Syn-(96-140)) did not protect GST from heat-induced
precipitation (Fig. 1A, line 4), whereas Syn-(61-140) containing the NAC region and the acidic tail appeared to
protect GST from heat-induced precipitation almost as effectively as
the wild type
-synuclein (Fig. 1A, lines 3 and
2, respectively). This result suggests that Syn-(61-140)
has all the units necessary for chaperone activity. Similar results
were obtained when aldolase was used as the substrate for the chaperone
activity assay (Fig. 1B).

View larger version (24K):
[in a new window]
Fig. 1.
Chaperone-like activity of
-synuclein and its deletion mutants.
A and B, thermally induced aggregation assay.
A, aggregation curves of GST (0.2 mg/ml in PBS, pH 7.4) at
65 °C in the absence and presence of
-synuclein deletion mutants.
Lines: 1, GST alone; 2, GST +
-synuclein (0.2 mg/ml); 3, GST + Syn-(61-140) (0.2 mg/ml); 4,
GST + Syn-(96-140) (0.2 mg/ml); 5,
-synuclein (0.2 mg/ml) alone; 6, Syn-(61-140) (0.2 mg/ml) alone;
7, Syn-(96-140) (0.2 mg/ml) alone. B,
aggregation curves of aldolase (0.2 mg/ml in PBS, pH 7.4) at 65 °C
in the absence and presence of
-synuclein deletion mutants.
Lines: 1, aldolase alone; 2, aldolase +
-synuclein (0.2 mg/ml); 3, aldolase + Syn-(61-140) (0.2 mg/ml); 4, aldolase + Syn-(96-140) (0.2 mg/ml).
C and D, DTT-induced aggregation assay.
C, aggregation curves of insulin (0.5 mg/ml in 10 mM phosphate buffer, pH 7.4) induced with 20 mM
DTT in the absence and presence of
-synuclein deletion mutants.
Lines: 1, insulin alone; 2, insulin +
-synuclein (0.5 mg/ml); 3-5, insulin + Syn-(61-140)
(1:1, 1:0.5, and 1:0.1, w/w, respectively); 6, insulin + Syn-(96-140) (0.5 mg/ml). D, aggregation curves of lysozyme
(0.5 mg/ml in 10 mM phosphate buffer, pH 7.4) induced with
20 mM DTT in the absence and presence of
-synuclein
deletion mutants. Lines: 1, lysozyme alone; 2,
lysozyme +
-synuclein (1:1, w/w); 3 and 4,
lysozyme + Syn-(61-140) (1:1 and 1:0.2, w/w, respectively).
-synuclein deletion
mutants by measuring the chemically induced aggregation of insulin and
lysozyme (Fig. 1, C and D). Consistent with the results obtained from the heat-induced precipitation assay,
Syn-(96-140) did not protect the substrate proteins from DTT-induced
precipitation (Fig. 1C, line 6). On the other
hand, Syn-(61-140) effectively protected the substrate proteins from
DTT-induced precipitation (Fig. 1, C, lines 3-5,
and D, lines 3 and 4). Interestingly,
Syn-(61-140) appeared to be much more efficient than wild type
-synuclein (Figs. 1, C and D, line 2) in terms
of protecting the substrate proteins from DTT-induced precipitation.
This aggregation was almost completely suppressed at an insulin to
chaperone weight ratio of 1:0.5, corresponding to a stoichiometric
ratio of 1:0.3 (Fig. 1C, line 4). Syn-(61-140)
also appeared to protect lysozyme from DTT-induced aggregation at a
substoichiometric ratio (Fig. 1D, line 4).
Syn-(61-140), Syn-(96-140), and wild type
-synuclein alone did not
precipitate under these conditions (data not shown). These results
indicate that the C-terminal acidic tail of
-synuclein was
necessary, but not sufficient for the chaperone activity of
-synuclein, and also suggest that the N-terminal region (residues 1-95) of
-synuclein may determine the efficiency of the chaperone function.
-crystallin, tubulin, and clusterin, prevent protein
precipitation by forming soluble HMW complexes (27, 32-40). We first
confirmed that
-synuclein also acts in this way to prevent protein
precipitation, and then investigated which region of
-synuclein was
critical for substrate protein binding (Fig.
2). The substrate protein (GST) was
incubated with wild type
-synuclein or its C-terminal fragment
(Syn-(96-140)) for 10 min at 65 °C and the protein mixtures were
purified on a FPLC gel-filtration column. Each peak fraction was then
analyzed on SDS-polyacrylamide gels. As expected,
-synuclein formed
a soluble HMW complex with the substrate protein (Fig. 2A).
Syn-(61-140) also appeared to form a HMW complex with GST (data not
shown). In contrast, the C-terminal acidic tail of
-synuclein (Syn-(96-140)) did not form a HMW complex (Fig. 2B), which
suggested that substrate protein binding may be mediated by the
N-terminal region of
-synuclein. Unlike other small molecular
chaperone proteins, however, the HMW complex formed between
-synuclein and GST contained only a trace amount of
-synuclein,
which was detected by immunoblotting (Fig. 2A,
f). The immunoreactivity of
-synuclein was only detected
in fractions corresponding to the HMW complex, indicating that these
HMW forms of
-synuclein were not contaminated by the
aggregates. A similar phenomenon was observed when other substrate
proteins were used (data not shown). Previous studies have shown that
Syn-(1-97) precipitates upon heat treatment and does not have the
chaperone activity (24). In addition, NAC and the C-terminal truncated
-synuclein have been shown to aggregate faster than the full-length
-synuclein (61-64). Taken together, it is highly likely that the
N-terminal region of
-synuclein functions as a binding domain for
substrate proteins and that the C-terminal acidic tail functions as a
solubilizing domain for the HMW complexes and for
-synuclein
itself.

View larger version (30K):
[in a new window]
Fig. 2.
The N-terminal region of
-synuclein mediates substrate protein binding.
A, FPLC gel-filtration chromatography (a-d) and
SDS-PAGE (e and f) analysis of the HMW complex of
wild type
-synuclein and GST. Protein samples (500 µl) were loaded
onto the Superdex 75 HR column (Amersham Biosciences) equilibrated in
PBS, and eluted at a flow rate of 1 ml/min at room temperature.
a, GST (0.1 mg/ml). b,
-synuclein (0.5 mg/ml).
-Synuclein incubated at 65 °C for 10 min was eluted at the same
position (data not shown). c, GST (0.1 mg/ml) +
-synuclein (0.5 mg/ml) were mixed and loaded onto the column.
d, GST (0.1 mg/ml) +
-synuclein (0.5 mg/ml) were mixed
and incubated for 10 min at 65 °C and then loaded onto the column.
e, SDS-PAGE analysis of the
-synuclein·GST
complex. The peak fractions numbered in a-d were
separated on a 12% SDS-polyacrylamide gel and stained with Coomassie
Brilliant Blue R-250. f, Western blot was performed to
detect
-synuclein in the HMW complex (containing peak fractions 3-5
from d). B, FPLC gel-filtration chromatography
(a-d) and SDS-PAGE (e) analysis of the
Syn-(96-140)·GST complex. a, GST (0.2 mg/ml).
b, Syn-(96-140) (0.2 mg/ml). c, GST (0.2 mg/ml) + Syn-(96-140) (0.2 mg/ml) were mixed and loaded onto the column.
d, GST (0.2 mg/ml) + Syn-(96-140) (0.2 mg/ml) were mixed
and incubated for 10 min at 65 °C and then loaded onto the column.
The arrow indicates the expected position for GST.
e, SDS-PAGE analysis of the Syn-(96-140)·GST complex. The
peak fractions numbered in a-d were separated on
a 12% SDS-polyacrylamide gel and stained with Coomassie Brilliant Blue
R-250. Lanes: 1, Syn-(96-140); 2, GST;
3, peak 3 from d; 4, pellet fraction
obtained after incubating the Syn-(96-140)/GST mixture for 10 min at
65 °C.
-synuclein. Based on this finding, we
hypothesized that the binding domain could be substituted by other
proteins, because the binding domain of molecular chaperone proteins
was not likely to be specific for individual substrate proteins. The
chaperone activity of Syn-(61-140) (Fig. 1) supports this idea. To
prove this hypothesis further, we constructed a GST-synuclein fusion
protein, GST-Syn-(96-140), containing the acidic tail of
-synuclein
at the C terminus of GST. Surprisingly, GST-Syn-(96-140) prevented GST
and aldolase from heat-induced precipitation (Fig.
3, A and B).
Furthermore, GST-Syn-(96-140) appeared to be a more efficient
chaperone protein than wild type
-synuclein and Syn-(61-140) (Figs.
1, A and B, 3, A and B),
and almost completely prevented GST and aldolase from heat-induced precipitation when they were incubated at a ratio of 1:1 (w/w) (Fig. 3,
A, line 4, and B, line 4).
However, GST-Syn-(96-140) was not as effective as
-synuclein at
protecting proteins from chemically induced precipitation (Fig. 3,
C and D). In particular, GST-Syn-(96-140) did
not prevent lysozyme from DTT-induced precipitation, although it
slightly alleviated the DTT-induced precipitation of insulin.

View larger version (23K):
[in a new window]
Fig. 3.
Chaperone-like activity of
GST-Syn-(96-140). A and B, thermally
induced aggregation assay. A, aggregation curves of GST (0.2 mg/ml in PBS, pH 7.4) at 65 °C in the absence and presence of
GST-Syn-(96-140). Lines: 1, GST alone; 2-4, GST + GST-Syn-(96-140) (1:0.1, 1:0.5, and 1:1, w/w, respectively);
5, GST-Syn-(96-140) (0.2 mg/ml) alone. B,
aggregation curves of aldolase (0.2 mg/ml in PBS, pH 7.4) at 65 °C
in the absence and presence of GST-Syn-(96-140). Lines: 1,
aldolase alone; 2-4, aldolase + GST-Syn-(96-140) (1:0.2,
1:0.5, and 1:1, w/w, respectively). C and D,
DTT-induced aggregation assay. C, aggregation curves of
insulin (0.5 mg/ml in 10 mM phosphate buffer, pH 7.4)
induced with 20 mM DTT in the absence and presence of
GST-Syn-(96-140). Lines: 1, insulin alone; 2-4,
insulin + GST-Syn-(96-140) (1:1, 1:3, and 1:5, w/w, respectively);
5, GST-Syn-(96-140) (0.5 mg/ml) alone. D,
aggregation curves of lysozyme (0.5 mg/ml in 10 mM
phosphate buffer, pH 7.4) induced with 20 mM DTT in the
absence and presence of GST-Syn-(96-140). Lines: 1,
lysozyme alone; 2 and 3, insulin + GST-Syn-(96-140) (1:1 and 1:3, w/w, respectively).
-synuclein,
GST-Syn-(96-140) appeared to form HMW complexes with a stoichiometric
ratio (Fig. 4, d and f, lanes 3-6),
which suggests that it interacts with substrate proteins in a similar
way to the sHSPs. These results indicate that the binding domain of
-synuclein can be substituted with another protein or peptide and
the resultant engineered protein functions as a molecular chaperone
with a different efficiency and specificity.

View larger version (20K):
[in a new window]
Fig. 4.
FPLC gel-filtration chromatography
(a-e) and SDS-PAGE (f) analysis of the HMW
complex between GST-Syn-(96-140) and aldolase. Protein samples
(500 µl) were loaded onto the Superdex 75 HR column (Amersham
Biosciences) equilibrated in PBS, and eluted at a flow rate of 1 ml/min
at room temperature. a, aldolase (0.2 mg/ml). b,
GST-Syn-(96-140) (0.2 mg/ml). c, aldolase (0.2 mg/ml) and
GST-Syn-(96-140) (0.2 mg/ml) were mixed and loaded onto the column.
d, aldolase (0.2 mg/ml) and GST-Syn-(96-140) (0.2 mg/ml)
were mixed and incubated for 10 min at 65 °C and then loaded onto
the column. e, GST-Syn-(96-140) (0.2 mg/ml) were incubated
for 10 min at 65 °C and then loaded onto the column. f,
SDS-PAGE analysis of the HMW complex. The peak fractions
numbered in a-d were separated on a 12%
SDS-polyacrylamide gel and stained with Coomassie Brilliant Blue
R-250.
-synuclein have
chaperone activity, we constructed a DHFR-synuclein fusion protein,
DHFR-Syn-(96-140), which contains the acidic tail of
-synuclein at
the C terminus. Interestingly, DHFR-Syn-(96-140) was extremely heat
resistant, whereas DHFR was so heat-labile that it easily precipitated
by thermal stress (data not shown). Similar phenomenon has been
observed when GST was fused with the acidic tail of
-synuclein (59).
We next examined the chaperone activity of DHFR-Syn-(96-140). As shown
in Fig. 5, DHFR-Syn-(96-140) effectively
protects aldolase from heat-induced aggregation, indicating that the
fusion protein functions as a molecular chaperone. DHFR-Syn-(96-140) also appeared to prevent GST from heat-induced precipitation (data not
shown). Therefore, it is highly likely that the C-terminal acidic tail
of
-synuclein can be used to engineer synthetic chaperones.

View larger version (16K):
[in a new window]
Fig. 5.
Chaperone-like activity of
DHFR-Syn-(96-140). Aggregation curves of aldolase (0.2 mg/ml in
PBS, pH 7.4) at 65 °C in the absence and presence of
DHFR-Syn-(96-140). Lines: 1, aldolase alone;
2-4, aldolase + DHFR-Syn-(96-140) (1:0.5, 1:1, and 1:2,
w/w, respectively); 5, DHFR-Syn-(96-140) (0.2 mg/ml)
alone.
-synuclein as a solubilizing domain
display different chaperone activities and substrate specificities, and
that these differences might originate from the intrinsic properties of
the binding domain. For example, Syn-(61-140) appeared to be a better chaperone than wild type
-synuclein at preventing the DTT-induced precipitation of substrate proteins (Fig. 1, C and
D). Furthermore, GST-Syn-(96-140) appeared to inhibit the
heat-induced precipitation of substrate proteins far more so than wild
type
-synuclein or Syn-(61-140) (Fig. 3, A and
B), but to only weakly suppress the DTT-induced
precipitation of substrate proteins (Fig. 3, C and D). To confirm the notion that the binding domain might
determine the efficiency and specificity of the chaperone function, we
induced conformational changes in GST-Syn-(96-140) by heating, and
examined changes in its chaperone-like activity during the DTT-induced aggregation of insulin. The conformation of GST-Syn-(96-140) was irreversibly changed at high temperatures with a melting temperature (Tm) of 62 °C (59), but insulin alone did not
precipitate at this temperature (data not shown). Interestingly, the
chaperone activity of GST-Syn-(96-140) in the DTT-induced aggregation
of insulin was significantly improved at 59 °C (Fig.
6A) compared with the case at
room temperature (Fig. 3C), suggesting that the efficiency
of its chaperone action was affected by conformational changes in its
N-terminal substrate-binding domain (GST domain in this case). In
addition, we found that GST-Syn-(96-140) did not protect the
heat-induced aggregation of luciferase, whereas
-synuclein and
Syn-(61-140) effectively prevented this aggregation (Fig.
6B). Therefore, it seems highly likely that the binding domain determines the efficiency and specificity of the chaperone function.

View larger version (14K):
[in a new window]
Fig. 6.
Substrate specificity of GST-Syn-(96-140) as
a molecular chaperone. A, temperature effect on the
chaperone-like activity of GST-Syn-(96-140). Protein mixtures were
preincubated for 5 min at 59 °C, then 2 mM DTT was added
to induce the aggregation of insulin, and mixtures were then placed on
a thermostatic cell holder. Lines: 1, insulin (0.5 mg/ml)
alone; 2, insulin + GST-Syn-(96-140) (1:1, w/w);
3, insulin + GST-Syn-(96-140) (1:0.5, w/w); and
4, GST-Syn-(96-140) (0.5 mg/ml) alone. B,
GST-Syn-(96-140) did not protect luciferase from heat-induced
aggregation. Protein mixtures were incubated for 10 min at 65 °C,
and light scattering was measured at 360 nm. Graphs: 1,
luciferase (0.1 mg/ml) alone at room temperature; 2,
luciferase (0.1 mg/ml) alone at 65 °C; 3, luciferase + GST-Syn-(96-140) (1:1, w/w) at 65 °C; 4, luciferase + Syn-(61-140) (1:1, w/w) at 65 °C.
-synuclein did not protect GST enzyme from heat-induced inactivation (25). To investigate whether GST-Syn-(96-140) was able to
protect enzymes from thermal inactivation, the thermostabilities of GST
and protein-tyrosine phosphatase-1B were measured using thermal
inactivation curves in the presence and in the absence of the
GST-Syn-(96-140) (Fig. 7). The thermal
inactivation curves were used to determine the
T50 values, the temperatures at which 50% of
initial enzymatic activity was lost after heat treatment. As shown in
Fig. 7, T50 values of GST and protein-tyrosine
phosphatase-1B appeared to be similar in the presence and absence of
the chaperone protein. This suggests that GST-Syn-(96-140) was
incapable of protecting enzymes from thermal inactivation, although it
can prevent the enzymes from thermal aggregation.

View larger version (14K):
[in a new window]
Fig. 7.
Thermal inactivation curves of GST
(A) and protein-tyrosine phosphatase-1B
(B) in the presence and absence of
GST-Syn-(96-140). Activity is expressed as a percentage of
initial activity. Values are the means of three independent
experiments, and the standard deviation is shown as bars.
The protein samples were incubated for 5 min at the indicated
temperatures, and the enzymatic activities were measured as described
under "Experimental Procedures" at 37 °C.
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
-Synuclein has been suggested to work as a chaperone protein in
mammalian cells (18), and recent studies have shown that
-synuclein
acts as a chaperone in vitro, and that the C-terminal truncated form of
-synuclein (Syn-(1-97)) has no chaperone activity (24, 25). In this study, we have shown that the C-terminal acidic tail
itself (Syn-(96-140)) does not interact with the substrate protein and
consequently does not protect the protein from stress-induced aggregation. However, in common with wild type
-synuclein, an N-terminal truncated form of
-synuclein (Syn-(61-140)) binds the
substrate protein and retains the chaperone activity, albeit with a
slightly different efficiency and substrate specificity. This indicates
that the N-terminal region of
-synuclein (residues 1-95) plays a
critical role in substrate protein binding, and that the C-terminal
acidic tail might function to solubilize the HMW complex (Fig.
8). Interestingly, the N-terminal-binding
domain can be substituted by other proteins or peptides, such as GST, DHFR, or NAC peptide (Fig. 8), and the resulting fusion proteins were
also found to have chaperone activity. More importantly, the synthetic
chaperone proteins appear to display differential chaperone activity in
terms of their efficiencies and substrate specificities (Figs. 1, 3,
and 6).

View larger version (37K):
[in a new window]
Fig. 8.
Distinct roles of the N-terminal-binding
domain and the C-terminal-solubilizing domain of
-synuclein in its molecular chaperone
function. Proteins containing both the binding domain and the
solubilizing domain exhibit chaperone-like activity.
The N-terminal part of
-synuclein (residues 1-61) is homologous to
the chaperone protein 14-3-3 (18). Consequently,
-synuclein and
14-3-3 bind to many of the same proteins, such as PKC, BAD, ERK,
and tyrosine hydroxylase (18, 22).
-Synuclein was also able to bind
to 14-3-3, tau protein, tubulin, synphilin-1, and phospholipase
D2 with high specificity and affinity (16-21).
Furthermore, expression of
-synuclein was greatly increased in 293 HEK cells under stress conditions (18). Based on these observations, it has been suggested that
-synuclein functions as a chaperone protein in vivo (18). This hypothesis has been supported by the
in vitro chaperone activity of
-synuclein reported
recently (24, 25). However,
-synuclein appears to be a much weaker
chaperone than HSP27 in preventing thermally induced aggregation of
alcohol dehydrogenase and chemically induced aggregation of insulin
in vitro (24). Our data also indicate that
-synuclein can
protect target proteins from stress-induced aggregation only at a
substoichiometric ratio (Fig. 1). Taken together, it seems likely that
-synuclein at least acts as a chaperone in vivo for
specific target proteins, like the case of the 14-3-3 chaperone.
Potential target proteins may include those proteins that are known to
associate with
-synuclein.
Most chaperone proteins have a flexible, hydrophilic tail that is
important for proper chaperone function. For example, GroEL is known to
have flexible N- and C-terminal tails, which protrude into the central
cavity of the molecule (66). SecB, a bacterial chaperone involved in
protein export, has been proposed to have a highly flexible C-terminal
region that is involved in binding to non-native proteins (67). X-ray
crystallographic and NMR spectroscopic analyses have shown that sHSPs,
such as HSP25, HSP16, and
-crystallin, contain a flexible C-terminal
extension (27-29, 68). Other small molecular chaperones, such as
clusterin and tubulin, are also known to have a flexible tail at the C
terminus (65, 69). These flexible, hydrophilic tails have been
suggested to play a critical role in substrate and chaperone protein
interactions, and to function as a solubilizer (26, 53-56). In fact, a
mutation in the C-terminal end or a deletion of the C-terminal end
caused a significant decrease in the chaperone activity of
-crystallin (55, 57). Tubulin also lost its chaperone-like activity
when the C-terminal acidic tail was removed by protease digestion (69). A previous study showed that the removal of the C-terminal acidic tail
of
-synuclein abolished its chaperone activity (24). Our present
data indicate that the C-terminal acidic tail was indeed necessary, but
not sufficient for the chaperone function of
-synuclein. The acidic
tail itself does not have chaperone activity, and does not appear to
interact with the substrate protein. It is highly likely that the role
of the introduced acidic tail is to increase protein solubility by
electrostatic repulsions. It is well documented that the solubility of
a protein is approximately proportional to the square of the net charge
on the protein (70). In fact, introducing the acidic tail greatly
decreases the pI and hydropathy values of the fusion protein (59), and
the C-terminal truncated
-synuclein mutants are found to aggregate
faster than the full-length
-synuclein under the same conditions
(61-64). Furthermore, fusion proteins containing the
-synuclein
acidic tail (GST-Syn-(96-140) and DHFR-Syn-(96-140)) has
chaperone-like activity, which suggests that a possible role of the
acidic tail in chaperone function might involve solubilizing the
substrate-chaperone complex, as well as the chaperone protein itself.
We have shown that the N-terminal region of
-synuclein binds the
substrate protein forming a soluble HMW complex (Fig. 2). The
GST-Syn-(96-140) fusion protein also appears to form such a HMW
complex, suggesting that the GST domain interacts with the substrate
protein (Fig. 4). Interestingly, however, the efficiency of the
chaperone function of GST-Syn-(96-140) differs from that of wild type
-synuclein. GST-Syn-(96-140) appeared to be more efficient than
-synuclein at preventing GST and aldolase from heat-induced
aggregation, but less efficient at preventing DTT-induced aggregation
of insulin and lysozyme (Fig. 3). In addition, an N-terminal truncated
form of
-synuclein (Syn-(61-140)) appeared to be more efficient
than wild type
-synuclein at preventing proteins from DTT-induced
aggregation (Fig. 1). These results strongly suggest that the
N-terminal-binding domain plays a crucial role in the efficiency of the
chaperone function. This idea is further supported by the observation
that GST-Syn-(96-140) effectively prevents insulin from DTT-induced
aggregation at elevated temperatures (Fig. 6A). At the
elevated temperatures, the tertiary structure of GST must be changed
and the perturbed structure seems to become more favorable for
substrate protein binding. Furthermore, GST-Syn-(96-140) does not
protect luciferase from heat-induced aggregation (Fig. 6B),
although it effectively protects GST and aldolase (Fig. 3, A
and B) and
-synuclein was able to protect all these
molecules from heat-induced aggregation (Figs. 1, A and
B, and 6B). These results suggest that the
chaperone function of GST-Syn-(96-140) was much more specific/limited
than that of
-synuclein. Taken together, our data demonstrate that
the N-terminal-binding domain governs the efficiency and the substrate
specificity of the chaperone proteins.
The chaperone action of sHSPs requires a common step of substrate
protein binding and a subsequent step of solubilizing the HMW complex
of chaperone and substrate protein (27, 32-40). The present study
demonstrates that
-synuclein functions in the same manner as the
sHSPs;
-synuclein prevents protein aggregation by binding substrate
protein and subsequently by solubilizing the HMW complex. Furthermore,
our results show that the substrate-binding domain and the solubilizing
domain are clearly separated in
-synuclein; the N-terminal region
(residues 1-95) binds the substrate protein and the C-terminal acidic
tail (residues 96-140) solubilizes the HMW complex. Unlike
-synuclein, however, sHSPs do not appear to have well separated
substrate-binding and -solubilizing domains. In the case of sHSPs, the
hydrophobic and the charged/hydrophilic regions are scattered through
the N- and C-terminal domains (49). sHSPs also have short, hydrophilic
extensions at the C terminus (10-15 residues), but these C-terminal
extensions play a significant role in substrate binding, as well as in
solubilizing the HMW complexes (54, 56). Furthermore, C-terminal
truncated forms of sHSPs still retain the chaperone activity, although
the chaperone activity is somewhat reduced and limited in some cases
(38, 51, 55, 57). This further suggests that the amino acid residues responsible for substrate binding and solubilizing sHSP-based HMW
complexes are scattered through the whole of the sHSP molecules.
The chaperone activity of sHSPs toward DTT- and UV-induced protein
aggregation is enhanced as the temperature increases, because the
conformation of sHSPs is presumably perturbed and consequently hydrophobic surfaces are more exposed at the higher temperatures (40,
71-76). A similar temperature-dependent interaction
between GroEL and substrate protein has been reported (77). The
chaperone-like activity of tubulin also becomes more pronounced as
temperature increases (69). Previously, we reported that preheating
-synuclein, which is believed to reorganize the molecular surface of
the protein, increases its chaperone activity (25). In this study, we
demonstrated that GST-Syn-(96-140) more efficiently protects insulin
from DTT-induced aggregation at 59 °C than at room temperature (Fig.
6A). Therefore, as has been observed for other molecular
chaperone proteins, temperature-induced structural perturbation of the
GST domain (substrate-binding domain) seems to be responsible for the
increased chaperone-like activity observed at higher temperatures.
The list of the new small molecular chaperones discovered is increasing
quite steadily, and recently tubulin, clusterin, and nucleolar protein
B23 have been added as new members (65, 69, 78). Tubulin also has a
C-terminal acidic tail and the removal of this tail abolishes its
chaperone-like activity (69). Clusterin contains three putative
amphipathic
-helical regions that might mediate interaction with
hydrophobic molecules (65), and nucleolar protein B23 has been reported
to have chaperone-like activity through a similar mechanism (78). These
chaperone proteins (tubulin, clusterin, and B23) have no amino acid
sequence similarity with either sHSPs or
-synuclein. Therefore, it
would be interesting to compare detailed molecular mechanisms of the
chaperone action mediated by these molecules with those of
-synuclein and sHSPs.
In summary, the results of this study indicate that the N-terminal
region of
-synuclein binds substrate protein and forms a HMW
complex, whereas the C-terminal acidic tail solubilizes the HMW complex
during the chaperone action. Because the substrate-binding domain and
the solubilizing domain are well separated in
-synuclein, the
N-terminal-binding domain can be substituted with other proteins or
peptides. Moreover, the resulting engineered chaperone proteins appear
to display different efficiencies and substrate specificities in terms
of the chaperone function. This implies that the C-terminal acidic tail
of
-synuclein can be utilized to engineer synthetic chaperones for
specific purposes simply by fusing the acidic tail with other proteins
or peptides. Such specifically designed chaperone proteins would be
useful for stabilizing target proteins both in vitro and
in vivo.
| |
ACKNOWLEDGEMENTS |
|---|
We thank Dr. R. Jakes (Medical Research
Council, Cambridge) for the recombinant DNA of
-synuclein, and Dr.
H. S. Rhim (The Catholic University, Seoul, Korea) for the
GST-synuclein fusion constructs.
| |
FOOTNOTES |
|---|
* This work was supported by Korea Science and Engineering Foundation (KOSEF) Grant 1999-2-209-014-5.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
¶ To whom correspondence and reprint requests should be addressed: Dept. of Microbiology, Yonsei University College of Medicine, 134 Shinchon-dong, Seodaemoon-gu, Seoul 120-752, Korea. Tel.: 82-2-361-5277; Fax: 82-2-392-7088; E-mail: jkim63@yumc.yonsei.ac.kr.
Published, JBC Papers in Press, May 24, 2002, DOI 10.1074/jbc.M111971200
| |
ABBREVIATIONS |
|---|
The abbreviations used are:
NAC, non-A
component of Alzheimer's disease amyloid;
GST, glutathione
S-transferase;
HMW complex, high molecular weight complex;
sHSP, small heat shock protein;
DHFR, dihydrofolate reductase;
DTT, dithiothreitol;
FPLC, fast protein liquid chromatography;
PBS, phosphate-buffered saline.
| |
REFERENCES |
|---|
|
|
|---|
| 1. |
Ueda, K.,
Fukushima, H.,
Masliah, E.,
Xia, Y.,
Iwai, A.,
Yoshimoto, M.,
Otero, D., A.,
Kondo, J.,
Ihara, Y.,
and Saitoh, T.
(1993)
Proc. Natl. Acad. Sci. U. S. A.
90,
11282-11286 |
| 2. | Jakes, R., Spillantini, M. G., and Goedert, M. (1994) FEBS Lett. 345, 27-32[CrossRef][Medline] [Order article via Infotrieve] |
| 3. | Spillantini, M. G., Schmidt, M. L., Lee, V. M., Trojanowski, J. O., Jakes, R., and Goedert, M. (1997) Nature 338, 839-840 |
| 4. |
Spillantini, M. G.,
Crowther, R. A.,
Jakes, R.,
Hasegawa, M.,
and Goedert, M.
(1998)
Proc. Natl. Acad. Sci. U. S. A.
95,
6469-6473 |
| 5. | Eliezer, D., Kutluay, E., Bussell, R., and Browne, G. (2001) J. Mol. Biol. 307, 1061-1073[CrossRef][Medline] [Order article via Infotrieve] |
| 6. | Kim, J. (1997) Mol. Cells 7, 78-83[Medline] [Order article via Infotrieve] |
| 7. | Weinreb, P. H., Zhen, W., Poon, A. W., Conway, K. A., and Lansbury, P. T., Jr. (1996) Biochemistry 35, 13709-13715[CrossRef][Medline] [Order article via Infotrieve] |
| 8. |
Lavedan, C.
(1998)
Genome Res.
8,
871-880 |
| 9. | Lücking, C. B., and Brice, A. (2000) Cell. Mol. Life Sci. 57, 1894-1908[CrossRef][Medline] [Order article via Infotrieve] |
| 10. | Iwai, A. (2000) Biochim. Biophys. Acta 1502, 95-109[Medline] [Order article via Infotrieve] |
| 11. | Hashimoto, M., and Masliah, E. (1999) Brain Pathol. 9, 707-720[Medline] [Order article via Infotrieve] |
| 12. |
Davison, W. S.,
Jonas, A.,
Clayton, D. F.,
and George, J. M.
(1998)
J. Biol. Chem.
273,
9443-9449 |
| 13. |
Ji, H.,
Liu, Y. E.,
Jia, T.,
Wang, T.,
Liu, J.,
Xiao, G.,
Joseph, B. K.,
Rosen, C.,
and Shi, Y. E.
(1997)
Cancer Res.
57,
759-764 |
| 14. | Surguchov, A., Surgucheva, I., Solessio, E., and Baehr, W. (1999) Mol. Cell Neurosci. 13, 95-103[CrossRef][Medline] [Order article via Infotrieve] |
| 15. | Abeliovich, A., Schmitz, Y., Farinas, I., Choi-Lundberg, D., Ho, W. H., Castillo, P. E., Shinsky, N., Verdugo, J. M., Armanini, M., Ryan, A., Hynes, M., Phillips, H., Sulzer, D., and Rosenthal, A. (2000) Neuron 25, 239-252[CrossRef][Medline] [Order article via Infotrieve] |
| 16. | Jenco, J. M., Rawlington, A., Daniels, B., and Morris, A. J. (1998) Biochemistry 37, 4901-4909[CrossRef][Medline] [Order article via Infotrieve] |
| 17. | Engelender, S., Kaminsky, Z., Guo, X., Sharp, A. H., Amaravi, R. K., Kleiderlein, J. J., Margolis, R. L., Troncoso, J. C., Lanahan, A. A., Worley, P. F., Dawson, T. M., and Ross, C. A. (1999) Nat. Genet. 22, 110-114[CrossRef][Medline] [Order article via Infotrieve] |
| 18. |
Ostrerova, N.,
Petruelli, L.,
Farrer, M.,
Mehta, N.,
Choi, P.,
Hardy, J.,
and Wolozin, B.
(1999)
J. Neurosci.
19,
5782-5791 |
| 19. | Skoulakis, E. M., and Davis, R. L. (1998) Mol. Neurobiol. 16, 269-284[Medline] [Order article via Infotrieve] |
| 20. |
Jensen, H. P.,
Hager, H.,
Nielsen, M. S.,
Hojrup, P.,
Gliemann, J.,
and Jakes, R.
(1999)
J. Biol. Chem.
274,
25481-25489 |
| 21. | Payton, J. E., Perrin, R. J., Calyton, D. F., and George, J. M. (2001) Mol. Brain Res. 95, 138-145[Medline] [Order article via Infotrieve] |
| 22. |
Perez, R. G.,
Waymire, J. C.,
Lin, E.,
Liu, J. J.,
Guo, F.,
and Zigmond, M. J.
(2002)
J. Neurosci.
22,
3090-3099 |
| 23. | Tzivion, G., Luo, Z., and Avruch, J. (1998) Nature 394, 88-92[CrossRef][Medline] [Order article via Infotrieve] |
| 24. | Souza, J. M., Giasson, B. I., Lee, V. M., and Ischiropoulos, H. (2000) FEBS Lett 474, 116-119[CrossRef][Medline] [Order article via Infotrieve] |
| 25. | Kim, T. D., Paik, S. R., Yang, C. H., and Kim, J. (2000) Protein Sci. 9, 2489-2496[Abstract] |
| 26. | Lindner, R. A., Carver, J. A., Ehrnsperger, M., Buchner, J., Esposito, G., Behlke, J., Lutsch, G., Kotlyarov, A., and Gaestel, M. (2000) Eur. J. Biochem. 267, 1923-1932[Medline] [Order article via Infotrieve] |
| 27. | van MontFort, R. L. M., Basha, E., Friedrish, K. L., Slingsby, C., and Vierling, E. (2001) Nat. Struct. Biol. 8, 1025-1030[CrossRef][Medline] [Order article via Infotrieve] |
| 28. | Kim, K. K., Kim, R., and Kim, S. H. (1998) Nature 394, 595-599[CrossRef][Medline] [Order article via Infotrieve] |
| 29. | Carver, J. A., Esposito, G., Schwedersky, G., and Gaestel, M. (1995) FEBS Lett. 369, 305-310[CrossRef][Medline] [Order article via Infotrieve] |
| 30. |
Jakob, V.,
Gaestel, M.,
Engel, K.,
and Buchner, J.
(1993)
J. Biol. Chem.
268,
1517-1520 |
| 31. |
Horwitz, J.
(1992)
Proc. Natl. Acad. Sci. U. S. A.
89,
10449-10453 |
| 32. | Rao, P. V., Horowitz, J., and Zigler, J. S., Jr. (1993) Biochem. Biophys. Res. Commun. 190, 786-793[CrossRef][Medline] [Order article via Infotrieve] |
| 33. |
Manna, T.,
Sarkar, T.,
Poddar, A.,
Roychowdhury, H.,
Das, K. P.,
and Bhattacharyya, B.
(2001)
J. Biol. Chem.
276,
39742-39747 |
| 34. | Netzer, W. J., and Hartl, F. H. (1998) Trends Biochem. Sci. 23, 68-73[CrossRef][Medline] [Order article via Infotrieve] |
| 35. | Farahbakhsh, Z. T., Huang, Q. L., Ding, L. L., Altenbach, C., Steinhoff, H. J., Horwitz, J., and Hubbel, W. L. (1995) Biochemistry 34, 509-516[CrossRef][Medline] [Order article via Infotrieve] |
| 36. |
Das, K. P.,
Petrash, J. M.,
and Surewicz, W. K.
(1996)
J. Biol. Chem.
271,
10449-10452 |
| 37. | Lindner, R. A., Kapur, A., and Carver, J. A. (1997) J. Biol. Sci. 272, 27722-27729 |
| 38. |
Leroux, M. R.,
Melki, R.,
Gordon, B.,
Batelier, G.,
and Candido, E. P.
(1997)
J. Biol. Chem.
272,
24646-24656 |
| 39. | Ehrnsperger, M., Graber, S., Gaestel, M., and Buchner, J. (1997) EMBO J. 16, 221-229[CrossRef][Medline] [Order article via Infotrieve] |
| 40. | Haslbeck, M., Walke, S., Stromer, T., Ehrnsperger, M., White, H. E., Chen, S., Saibil, H. R. |